The mouse achaete-scute homolog-2 gene (Ascl2 or Mash2) encodes a transcription factor playing a role in the development of the trophoblast. The Ascl2 is an imprinted gene with maternal expression and assigned to an imprinting gene cluster region (ICR) at a distal region of mouse chromosome 7. We previously isolated a phage clone carrying the human homolog, ASCL2, and mapped it to human chromosome 11p15.5, a human ICR. In the present study, we demonstrate the expression patterns of the human ASCL2 in the fetus at a stage between first and second trimesters and in the placental tissues. In addition, it has been shown that the human ASCL2 gene escapes genomic imprinting.
INTRODUCTION
The Ascl (Mash) genes, Ascl1 and Ascl2, are vertebrate homologs of the achaete-scute genes required for neuronal determination in Drosophila (1) . The Ascl gene products are members of the basic helixloop-helix (bHLH) family of transcription factors. The mouse Ascl2(Mash2) is strongly expressed in the extraembryonic trophoblast lineage and plays a critical role in early development of trophoblast progenitors, but it does not directly involve the embryonic development itself (2) . A gene targeting approach demonstrated that the mouse embryos homozygous for the mutant Ascl2 died of a placental failure by 10 days postcoitum (2) . The expression is almost wholly attributable to embryonal transcripts at the late two-cell stage (3) . Around the time of implantation, Ascl2 becomes specific to diploid trophoblast cells and around Day 10, its expression is limited to the labyrinth layer and the outer spongiotrophoblast layer. After Day 10, the level of expression is declining until barely detectable at Day 18.5 (3) . The mouse Ascl2 has been reported to be involved in genomic imprinting with maternal-allele expression and assigned to a distal region of mouse chromosome 7, which corresponds to a mouse imprinting cluster region (ICR) containing the imprinted genes, Ipl, Impt1, Itm, Cd81, Kvlqt1, Ins2, Igf2, H19, and p57Kip2 (4) (5) (6) (7) (8) . We previously isolated a genomic clone covering the human ASCL2 and localized it to human chromosome 11p15.5 (9) within ICR close to IGF2, H19, and p57KIP2 (10) . In this study, we show the expression patterns of the human ASCL2 in the fetus at a stage between first and second trimesters and in the placental tissues. In addition, it has been demonstrated that the ASCL2 escapes genomic imprinting.
MATERIALS AND METHODS

Sequencing of the ASCL2 Region
The DNA from a human genomic phage clone (phHAS2-1) isolated in our previous work (9) was SmaI-cut and separated on 1.2% NuSieveTM agarose gel (FMC BioProducts, USA), and Southern hybridization was carried out using the rat Ascl2 probe as used previously (9) . The SmaI-digests were also loaded in 4% polyacrylamide gel, the DNA fragments were cut out and cloned into pUC19. An about 600-bp insert (Probe-1) was subcloned, sequenced, and used for further experiments. The phHAS2-1 digests with various restriction enzymes were subjected to Southern blot analysis using the Probe-1 as a probe. A 6.6-kb EcoRI-fragment (TM1) of phHAS2-1 which was hybridized to Probe-1 was subcloned into PUC19 and sequenced in both directions.
Rapid Amplification of cDNA Ends (RACE)
The total RNA (20 mg) was extracted from a 7-week-old human placenta, and cDNA was synthesized using an oligonucleotide, 3RACER as a primer. PCR (polymerase chain reaction) was carried out using the cDNAs as a template with a primer set, 3RACE1F/3RACE1R. A nested PCR was then performed for 10 cycles using another set, 3RACE2F/ 3RACE2R. Two nested PCR products, 145-bp NPC-1 and 349-bp NPC-2, were isolated, subcloned into pUC19, and sequenced to confirm to be derived from TM1. The oligonucleotides used to amplify were 5 -TGACCATCGCATGACGTGAGTACTG CAGGATGACTCGCCTTTTTTTTTTTTTTTTT-3 (3RACER), 5 -GGGGCACCAACACTTGGAGA-3 (3RACE1F), 5 -TGACCATCGCATGACGTG AG-3 (3RACE1R), 5 -GGGGAATTCTACACATT AACTTGAGCTG-3 (3RACE2F), and 5 -TACTG CAGGATGACTCGCC-3 (3RACE2R).
cDNA Library Screening
With the aim of the isolation of the ASCL2-cDNA, we screened cDNA libraries in Uni-ZAPTM XR vector (Stratagene) constructed from 9-week-old human villus tissues. Probe was prepared by means of reverse transcriptase-based (RT)-PCR, using the villus-derived total RNA as a template and using For1/Rev1 as primers. A seminested PCR was then performed using primers For1/Rev2. The oligonucleotides used to amplify cDNA were 5 -GGGGAA TTCGGCCCAGCCTGACCAATG-3 (For1), 5 -CC CAGGTCAAGGGTTCTTTG-3 (Rev1), 5 -TCCG TTTGCCAGCAGTGTC-3 (Rev2). The resultant product (RT1) was [a-32P] dCTP-labeled and used as a probe for a screening on the library. Isolated clones were confirmed by sequence analysis.
Northern Blot Analysis
To detect expression levels in a variety of tissues, the isolated cDNA was hybridized to ready-made filters (an RNA panel from the heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas) for northern blot analysis (Multiple Tissue Northern Blot, Clontech).
In Situ Hybridization
Four fetuses obtained through therapeutic abortions at a stage between first and second trimesters and placental tissues at 8-40 weeks of gestation were used. Ethical approval for the use of the human tissue was granted by the Ethics Committee. Serial 5-mm thick sections were cut from formalin-fixed, paraffin-embedded archival materials and mounted onto 2% aminopropyl triethoxysilane (Sigma) in acetone coated slides. The cDNA isolated was cloned into pBluescript KSII (-). Sense and antisense RNA transcribed from linearized templates using T7 and T3 RNA polymerases (Promega, USA) were labeled with 35S-CTP (Amersham, UK) to be used as probes. In situ hybridization and autoradiography were performed as described previously (11) .
RFLP Analysis
Genomic DNA was prepared from placentae with various stages of development, and parental DNA was extracted from their peripheral blood leukocytes. To search for an RFLP, PCR was performed using For1/Poly1 (5 -GGGGGAATTCACG CTCCCTTGAAGAGG-3 ) as a primer set, and PCR products cloned into pBluescript KSII (-) were sequenced. Total RNA was extracted from the same placentae with the guanidine thiocyanate method. The placental RNA was converted to the first-strand cDNA with oligo-dT 13-18 primer by M-MuLV reverse transcriptase. All the placental and maternal genomic DNA as well as placental RNA and cDNA were subjected to PCR with a primer pair, For1/ASC3. PCR products digested with SacII were electrophoresed on 8% polyacrylamide gel to detect parent-fetus transmissions of alleles.
RESULTS
Structure of the Human ASCL2 Region
We first constructed a restriction map of the insert of a human ASCL2-covering phage clone (phHAS2-1), and sequenced the 6.6-kb EcoRI fragment (TM1) of the insert. From the sequence result, two possible poly-adenylation-like signals were found 1458 and 1662 bp downstream of the bHLH domain, respectively. The findings suggested that TM1 contains the whole ASCL2 gene.
Isolation of the Human ASCL2 cDNA
The 3 -RACE amplified approximately 300-and 120-bp fragments. Since sequence analysis revealed that both RACE-products corresponded to a 3 -portion of TM1, the transcript might have two alternative poly A signals. As a highly amplified product (RT1) was obtained by RT-PCR, using placental RNA as a template and a primer pair of 3RACE1F/Rev1, irrespective of gestational ages of the placenta used. The screening of the 9 weeks' library using RT1 as a probe gave seven positive clones and all clones were sequenced. All of them include the 3 UTR of the ASCL2 cDNA.
Expression Analysis of the Human ASCL2
To know the expression levels of the ASCL2 in a variety of tissues and developmental stages, northern blot analysis and in situ hybridization analysis were carried out. Northern hybridization revealed 1.6-kb band in the mature placenta (Fig. 1) . The in situ hybridization demonstrated a high level of the transcripts in the placentae at a stage between the first and second trimesters (Fig. 2) . Abundant transcripts were localized in the intermediate trophoblasts, while the expression level was low in the cytotrophoblasts and stroma of chorionic villi. The signal was regarded as specific, since the tissues hybridized with sense probes did not show any detectable signals. On the other hand, syncitiotrophoblasts showed only trace signals (data not shown). The hybridization using a whole mount fetus from the second trimester demonstrated that the ASCL2 appeared to be localized specifically in the ectoderm but not in the mesoderm or endoderm. A moderate amount of the ASCL2 was detected in photoreceptor, bipolar, and ganglion cells of the retina, and in primitive skin cells (Fig. 2) . Primitive neuronal cells of the brain expressed a low-tomoderate amount of the transcripts (Fig. 3) . A similar amount of signals was also detected in neuronal cells in the spinal cord, but not in the peripheral nerve. In addition, the choroid plexus show strong signals, the level of which was comparable to that of the placenta.
Biallelic Expression of the ASCL2 in the Placenta
We searched for a polymorphic site in ASCL2 cDNA to discriminate between its parental alleles (12) . Each of the genomic DNAs derived from 12-39-week's placentae was amplified by PCR using For1/Poly1 as a primer pair and then sequenced. In 16 of 55 placentae examined, a G to C substitution, a silent mutation, was found at the ASCL2 3 UTR region. Since the substitution loses a SacII recognition site, PCR products from the placental DNAs were digested with the enzyme, and the SacII RFLP was confirmed (data not shown). We then examined on whether each parental allele was expressed in the ASCL2 from the 16 placentae which were heterozygous for the polymorphic alleles. All of the SacII digests of RT-PCR products from the 16 placentae showed biparental expression (Fig. 4) .
DISCUSSION
The mouse Ascl2 is the first transcription factor shown to play a critical part in the development of the mammalian trophoblast lineage. At postimplantation stage the mouse Ascl2 is abundantly expressed in the ectoplacental cone and extraembronic ectoderm of the Day 7.5. At Day 8.5 expression persists at high levels in all the diploid trophoblast cells (3) . At that time, lower levels of expression are also detected in the embryo (2) . At Day 9.5-10.5, expression persists in both the labyrinthine layer and outer spongiotrophoblast layer. Beyond Day 10, expression levels began to decline. In this study, we showed the expression patterns of the human ASCL2 in placentae at a stage between the first and second trimesters (Fig. 2) . Abundant transcripts were detected in the intermediate trophoblasts, while the levels were low in the cytotrophoblasts and stroma of chorionic villi. On the other hand, the ASCL2 was localized specifically in the ectoderm by hybridization using a whole mount fetus from the second trimester (Fig. 3) . The expression patterns resembling those for the mouse Ascl2. It remains to be seen what roles the human ASCL2 plays in the development of the placenta and ectoderm.
At the present, there are two hypotheses on whether the human ASCL2 is imprinted or not. The first one is following: It was suggested that the ASCL2 is also imprinted in man by in situ hybridization methods, using the trophoblast cells of moles (13) . The other one is following: The ASCL2 is expressed biallelicaly by analysis using only early placental tissues (weeks 5-10 of gestation) (14) . The expression patterns of imprinting genes are sometimes different depending on the embryonic stage. For example, the mouse Ascl2 is biallelically expressed from 6.5 to 7.5 days postcoitum (5) . In this study, we analyzed the imprinting with a variety stage of placentae (Weeks 12-39 of gestation). All of them displayed biallelic expression patterns. Then we can exclude the possibilities of stage-dependent imprinting. In addition, we analyzed a total of 16 samples and all of them escaping genomic imprinting. Then we can deny the possibility of the imprinting polymorphism (15) .
In conclusion, we showed the human ASCL2 expression patterns in detail and established that the human ASCL2 escapes from genomic imprinting.
